
Combating ARDS, the biggest threat to COVID-19 patients, may lead to new treatments for the condition, writes physician and biotech CEO Joe G. N. “Skip” Garcia.
Joe G. N. "Skip" Garcia, MD, a world-renowned pulmonary physician-scientist and an elected member of the National Academy of Medicine. He is an endowed professor of medicine at the University of Arizona College of Medicine â Tucson, and leads the Garcia Lab at the University of Arizona. Dr. Garcia also is a leading authority on the genetic basis of lung disease and the prevention and treatment of inflammatory lung injury including ARDS. He is also the CEO of Aqualung Therapeutics, a Tucson-based biotech company developing a novel, anti-inflammatory monoclonal antibody.

Published: April 7th 2020 | Updated: